RUC. Repositorio da Universidade da Coruña
Publicación
Artículo científico (JournalArticle)
In vitro development of imipenem/relebactam resistance in KPC-producing Klebsiella pneumoniae involves multiple mutations including OmpK36 disruption and KPC modification
[Abstract]
Objectives: In order to inform and anticipate potential strategies aimed at combating KPC-producing Klebsiella pneumoniae infections, we analysed imipenem/relebactam and ceftazidime/avibactam single-step mutant frequencies, resistance development trajectories, differentially selected resistance mechanisms and their associated fitness cost using four representative high-risk K. pneumoniae clones.
Methods: Mutant frequencies and mutant preventive concentrations were determined using agar plates containing incremental concentrations of β-lactam/β-lactamase inhibitor. Resistance dynamics were determined through incubation for 7 days in 10 mL MH tubes containing incremental concentrations of each antibiotic combination up to their 64 × baseline MIC. Two colonies per strain from each experiment were characterized by antimicrobial susceptibility testing, whole genome sequencing and competitive growth assays (to determine in vitro fitness). KPC variants associated with imipenem/relebactam resistance were characterized by cloning and biochemical experiments, atomic models and molecular dynamics simulation studies.
Results: Imipenem/relebactam prevented the emergence of single-step resistance mutants at lower concentrations than ceftazidime/avibactam. In three of the four strains evaluated, imipenem/relebactam resistance development emerged more rapidly, and in the ST512/KPC-3 clone reached higher levels compared to baseline MICs than for ceftazidime/avibactam. Lineages evolved in the presence of ceftazidime/avibactam showed KPC substitutions associated with high-level ceftazidime/avibactam resistance, increased imipenem/relebactam susceptibility and low fitness costs. Lineages that evolved in the presence of imipenem/relebactam showed OmpK36 disruption, KPC modifications (S106L, N132S, L167R) and strain-specific substitutions associated with imipenem/relebactam resistance and high fitness costs. Imipenem/relebactam-selected KPC derivatives demonstrated enhanced relebactam resistance through important changes affecting relebactam recognition and positioning.
Conclusions: Our findings anticipate potential resistance mechanisms affecting imipenem/relebactam during treatment of KPC-producing K. pneumoniae infections., This work was supported by MSD through the Investigator Initiated Studies Program, which provided financial support (to G.B.) and relebactam. This work was also supported by the Fondo de Investigación Sanitaria (grant numbers PI17/01482 and PI20/01212 for A.B. and PI18/00501 and PI21/00704 for G.B.) integrated in the Plan Nacional de I1D and funded by the Instituto de Salud Carlos III (ISCIII), CIBERINFEC (CIBER de Enfermedades Infecciosas). The research was also funded by the Spanish Network of Research in Infectious Diseases (REIPI), no. RD16/0016/0004 and no. RD16/0016/0006, integrated in the National Plan for Scientific Research, Development and Technological Innovation 2013–2016 and funded by the ISCIII–General Subdirection of Assessment and Promotion of the Research—European Regional Development Fund (FEDER) ‘A way of making Europe.’ The study was also funded by GAIN (Agencia Gallega de Innovacion, Conselleria de Economia, Emprego e Industria; IN607D2021/12, A.B. and IN607A 2016/22, G.B.). PGS was financially supported by IN606A-2021/021. I.A.-G was financially supported by the Rio Hortega program (ISCIII, CM21/00076). J.C.V.-U. was financially supported by the ISCIII project FI18/00315. C.L.-M. was financially supported by IN606A-2019/ 029. J.A.-S. was financially supported by the Juan Rodés program (ISCIII, JR21/00026). Financial support from the Spanish Agency of Research (PID2019-105512RB-I00/AEI/10.13039/501100011033, CG-B), the Xunta de Galicia [ED431C 2021/29 and the Centro singular de investigación de Galicia accreditation 2019–2022 (ED431G 2019/03), CG-B], and the European Regional Development Fund (ERDF) is gratefully acknowledged. AC acknowledges Banco Santander for his fellowship. We are also grateful to the Centro de Supercomputación de Galicia (CESGA) for use of the Finis Terrae computer., Xunta de Galicia; IN607D2021/12, Xunta de Galicia; IN607A 2016/22, Xunta de Galicia; IN606A-2021/021, Xunta de Galicia; ED431C 2021/29, Xunta de Galicia; ED431G 2019/03
Proyecto:
ISCIII / Plan Estatal de Investigación Científica y Técnica y de Innovación 2013-2016 PI17-01482
,
ISCIII / Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020 PI20-01212
,
ISCIII / Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020 PI18-00501
,
ISCIII / Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020 PI21-00704
,
MINECO / Plan Estatal de Investigación Científica y Técnica y de Innovación 2013-2016 RD16-0016-0004
,
MINECO / Plan Estatal de Investigación Científica y Técnica y de Innovación 2013-2016 RD16-0016-0001
,
MICINN / Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020 FI18-00315
,
ISCIII / Plan Estatal de Investigación Científica y Técnica y de Innovación 2021-2023 JR21-00026
,
AEI / Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020 PID2019-105512RB-I00
HANDLE: http://hdl.handle.net/2183/42149
Ver en: http://hdl.handle.net/2183/42149